Introduction Kaposiform lymphangiomatosis (KLA) is an ultrarare disease characterized by abnormal lymphatic vessel proliferation due to hyperactivation of the Rat sarcoma virus (RAS) signaling pathway, resulting in multifocal lymphatic malformations (LMs) that can potentially involve multiple organ systems. Its distinctive histologic features include the presence of clusters of spindle cells expressing clusters of differentiation 31 (CD31), cluster of differentiation 34 (CD34), podoplanin (D2-40), prospero homeobox protein 1 (PROX1), and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), along with abnormal lymphatic vessels. Sirolimus is recommended as a treatment option, particularly for patients without known mutations. This study aimed to examine the long-term therapeutic effects of sirolimus treatment in adult patients with KLA. Materials and methods Between 2016 and 2024, KLA was diagnosed in three women, aged 21, 35, and 46 years, based on clinical presentation, laboratory findings, and imaging studies, and the diagnosis was confirmed by histological examination. The administration of sirolimus was initiated in all three cases at a therapeutic dose. Results Treatment resulted in clinical improvement, partial regression, and subsequent stabilization of fluid volume in the pleural cavities, along with reductions in the severity of anemia and hypofibrinogenemia, accompanied by a decrease in D-dimer concentration. Sirolimus proved to be a relatively effective treatment in this group of KLA patients; however, some beneficial effects were not sustained after 5 years of follow-up. The most common side effects included mucositis and lipid disorders. We also reviewed the literature regarding sirolimus treatment in KLA patients. Conclusion Overall, sirolimus in KLA patients is an effective treatment option with acceptable toxicity.
Bilny-Paluch et al. (Thu,) studied this question.